Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Mutational inactivation and allelic loss of the von Hippel-Lindau (VHL) gene appear to be causal events for the majority of spontaneous clear-cell renal carcinomas. We now show that hypermethylation of a normally unmethylated CpG island in the 5' region provides another potentially important mechanism for inactivation of the VHL gene in a significant portion of these cancers. This hypermethylation was found in 5 of 26 (19%) tumors examined. Four of these had lost one copy of VHL while one retained two heavily methylated alleles. Four of the tumors with VHL hypermethylation had no detectable mutations, whereas one had a missense mutation in addition to hypermethylation of the single retained allele. As would be predicted for the consequence of methylation in this 5' CpG island, none of the 5 tumors expressed the VHL gene. In contrast, normal kidney and all tumors examined with inactivating VHL gene mutations but no CpG island methylation had expression. In a renal cell culture line, treatment with 5-aza-2'-deoxycytidine resulted in reexpression of the VHL gene. These findings suggest that aberrant methylation of CpG islands may participate in the tumor-suppressor gene inactivations which initiate or cause progression of common human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Self-citationRole for DNA methylation in genomic imprinting
Li, E., Beard, C., & Jaenisch, R. (1993) · Nature · doi:10.1038/366362a0 · Cited by 1,964
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
Hypomethylation of DNA from Benign and Malignant Human Colon Neoplasms
Goelz, S. E., Vogelstein, B., Hamilton, S. R., & Feinberg, A. P. (1985) · Science · doi:10.1126/science.2579435 · Cited by 840
High levels of De Novo methylation and altered chromatin structure at CpG islands in cell lines
Antequera, F., Boyes, J., & Bird, A. (1990) · Cell · doi:10.1016/0092-8674(90)90015-7 · Cited by 699
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma
Zbar, B., Brauch, H., Talmadge, C., & Linehan, M. (1987) · Nature · doi:10.1038/327721a0 · Cited by 638
Self-citationSTOGER, R. (1993) · Cell · doi:10.1016/0092-8674(93)90160-r · Cited by 598
Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma
Greger, V., Passarge, E., H�pping, W., Messmer, E., & Horsthemke, B. (1989) · Human Genetics · doi:10.1007/bf00286709 · Cited by 574
Reduced genomic 5-methylcytosine content in human colonic neoplasia.
Feinberg, A. P., Gehrke, C. W., Kuo, K. C., & Ehrlich, M. (1988) · PubMed · Cited by 568
Cited by
Items 101–157 of 157
DNA Methylation: An Alternative Pathway to Cancer
Wajed, S. A., Laird, P. W., & DeMeester, T. R. (2001) · Annals of Surgery · doi:10.1097/00000658-200107000-00003 · Cited by 327
Graff, J. R., Herman, J. G., Myöhänen, S., Baylin, S. B., & Vertino, P. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22322 · Cited by 319
Self-citationThe Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
Kaelin, W. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-sup-040025 · Cited by 318
Nuovo, G. J., Plaia, T. W., Belinsky, S. A., Baylin, S. B., & Herman, J. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12754 · Cited by 314
Self-citationGenetic analysis of von Hippel-Lindau disease
Nordstrom-O'Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., van Brussel, A., Voest, E. E., & Giles, R. H. (2010) · Human Mutation · doi:10.1002/humu.21219 · Cited by 311
Creation of genomic methylation patterns
Bestor, T. H., & Tycko, B. (1996) · Nature Genetics · doi:10.1038/ng0496-363 · Cited by 310
Sinclair, P. B., Nacheva, E. P., Leversha, M., Telford, N., Chang, J., Reid, A., Bench, A., Champion, K., Huntly, B., & Green, A. R. (2000) · Blood · doi:10.1182/blood.v95.3.738.003k21_738_743 · Cited by 310
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
Brugarolas, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2003 · Cited by 306
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
DNA methylation markers in colorectal cancer
Kim, M. S., Lee, J., & Sidransky, D. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9207-6 · Cited by 303
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
Li, L.-C., Carroll, P. R., & Dahiya, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji010 · Cited by 299
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 297
Salvesen, H. B., MacDonald, N., Ryan, A., Jacobs, I. J., Lynch, E. D., Akslen, L. A., & Das, S. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010101)91:1<22::aid-ijc1002>3.0.co;2-s · Cited by 294
Dreijerink, K., Braga, E., Kuzmin, I., Geil, L., Duh, F.-M., Angeloni, D., Zbar, B., Lerman, M. I., Stanbridge, E. J., Minna, J. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131216298 · Cited by 294
Self-citationDNA methylation in genomic imprinting, development, and disease
Paulsen, M., & Ferguson-Smith, A. C. (2001) · The Journal of Pathology · doi:10.1002/path.890 · Cited by 291
Progress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
CpG island methylator phenotypes in aging and cancer
Toyota, M., & Issa, J.-P. J. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1999.0135 · Cited by 288
Vertino, P. M., Yen, R.-W. C., Gao, J., & Baylin, S. B. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4555 · Cited by 288
Chanda, S., Dasgupta, U. B., GuhaMazumder, D., Gupta, M., Chaudhuri, U., Lahiri, S., Das, S., Ghosh, N., & Chatterjee, D. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj030 · Cited by 283
Bhat, G. R., Sethi, I., Sadida, H. Q., Rah, B., Mir, R., Algehainy, N., Albalawi, I. A., Masoodi, T., Subbaraj, G. K., Jamal, F., et al. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10172-z · Cited by 281
Altered methylation patterns in cancer cell genomes: Cause or consequence?
Baylin, S., & Bestor, T. H. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00061-2 · Cited by 280
Banks, R. E., Tirukonda, P., Taylor, C., Hornigold, N., Astuti, D., Cohen, D., Maher, E. R., Stanley, A. J., Harnden, P., Joyce, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3074 · Cited by 275
Kondo, Y., Kanai, Y., Sakamoto, M., Mizokami, M., Ueda, R., & Hirohashi, S. (2000) · Hepatology · doi:10.1053/jhep.2000.19797 · Cited by 273
Sidhar, S. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.9.1333 · Cited by 272
Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. C. M., & Maher, E. R. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-# · Cited by 270
Cancer Epigenetics: Modifications, Screening, and Therapy
Einav Nili, G.-Y., Saito, Y., Egger, G., & Jones, P. A. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061606.095816 · Cited by 270
Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes
Uchida, T., Kinoshita, T., Nagai, H., Nakahara, Y., Saito, H., Hotta, T., & Murate, T. (1997) · Blood · doi:10.1182/blood.v90.4.1403 · Cited by 269
Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches
Wong, C. C., Qian, Y., & Yu, J. (2017) · Oncogene · doi:10.1038/onc.2016.485 · Cited by 262
Harnessing synthetic lethal interactions in anticancer drug discovery
Chan, D. A., & Giaccia, A. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3374 · Cited by 262
Iliopoulos, O., Ohh, M., & Kaelin, W. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11661 · Cited by 260
Methylation and Silencing of the Retinoic Acid Receptor- 2 Gene in Breast Cancer
Widschwendter, M., Berger, J., Hermann, M., Muller, H. M., Amberger, A., Zeschnigk, M., Widschwendter, A., Abendstein, B., Zeimet, A. G., Daxenbichler, G., et al. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.10.826 · Cited by 259
The Role of DNA Methylation in Cancer
Lakshminarasimhan, R., & Liang, G. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-43624-1_7 · Cited by 259
Von Hippel-Lindau Syndrome: A pleomorphic condition
Friedrich, C. A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991201)86:11+<2478::aid-cncr4>3.0.co;2-5 · Cited by 258
Florl, A. R., Löwer, R., Schmitz-Dräger, B. J., & Schulz, W. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690524 · Cited by 255
Issa, J. P., Vertino, P. M., Boehm, C. D., Newsham, I. F., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11757 · Cited by 253
Genetic Basis of Cancer of the Kidney
Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., Vocke, C., Schmidt, L., Isaacs, J. S., Glenn, G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-050013 · Cited by 251
“Subsequent studies revealed VHL gene mutation or methylation in a high percentage of tumors from patients with sporadic, noninherited clear cell renal carcinoma (9, 10).”
BackgroundSelf-citation(1996) · PubMed · Cited by 242
Cancer epigenetics in clinical practice
Davalos, V., & Esteller, M. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21765 · Cited by 237
“Aberrant DNA methylation in cancer was first detected by Southern hybridization using restriction endonucleases that discriminate be- tween methylated and unmethylated CG sequences, such as HpaII, HhaI, or NotI.3,16,17 A crucial advance in the analysis of DNA methylation resulted from the demonstration that treatment…”
BackgroundCpG methylation as a mechanism for the regulation of E2F activity
Campanero, M. R., Armstrong, M. I., & Flemington, E. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100340697 · Cited by 230
The fundamental role of epigenetics in hematopoietic malignancies
Galm, O., Herman, J. G., & Baylin, S. B. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.01.006 · Cited by 230
Self-citationA Clearer View of the Molecular Complexity of Clear Cell Renal Cell Carcinoma
Frew, I. J., & Moch, H. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040306 · Cited by 220
Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer
Vanharanta, S., Shu, W., Brenet, F., Hakimi, A. A., Heguy, A., Viale, A., Reuter, V. E., Hsieh, J. J.-D., Scandura, J. M., & Massagué, J. (2013) · Nature Medicine · doi:10.1038/nm.3029 · Cited by 215
Searching for the hereditary causes of renal-cell carcinoma
Pavlovich, C. P., & Schmidt, L. S. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1364 · Cited by 209
“accompanied by inactivation of the wild-type copy of the VHL gene in a susceptible cell through LOSS OF HETEROZYGOSITY (LOH), promoter HYPERMETHYLATION or somatic mutation, according to the KNUDSON TWO-HIT TUMOUR-SUPPRESSOR MODEL”
MethodCpG Island Hypermethylation of Tumor Suppressor Genes in Human Cancer
Herranz, M., & Esteller, M. (2007) · Medical Intelligence Unit · doi:10.1007/0-387-27443-x_6 · Cited by 202
Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.12.004 · Cited by 191
Epigenetic gene silencing in cancer initiation and progression
Nephew, K. P., & Huang, T. H.-M. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00511-6 · Cited by 188
Aging, DNA methylation and cancer
Issa, J.-P. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00019-0 · Cited by 185
“In cancer, promoter hypermethylation has been linked to inactivation of tumor-suppressor genes such as RB1 [96], P16 [97], BRCA1 [98] and VHL [99], DNA repair genes such as hMLH1 [100] and MGMT [28], angiogenesis inhibitors such as THBS1 [101], growth-regulatory genes such as ER [102], PGR [103], and others.”
BackgroundCasillas, M. A., Lopatina, N., Andrews, L. G., & Tollefsbol, T. O. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1025548623524 · Cited by 181
“Certain tumors have been shown to have regional hypermethylation of CpG islands associated with the promoter regions of tumor suppressor genes, such as RB [13], VHL [14], p16INK4A [15], and hMLH1 [16], and the regional hypermethylation is often associated with the inactivation of the tumor suppressor genes [17].”
Yeo, E.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0233-3 · Cited by 175
HISTOPATHOLOGY AND MOLECULAR GENETICS OF RENAL TUMORS: TOWARD UNIFICATION OF A CLASSIFICATION SYSTEM
ZAMBRANO, N. R., LUBENSKY, I. A., MERINO, M. J., LINEHAN, W. M., & WALTHER, M. M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68259-6 · Cited by 167
Self-citationVHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
Cowey, C. L., & Rathmell, W. K. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0015-5 · Cited by 165
El-Osta, A., & Wolffe, A. P. (2001) · Gene Expression · doi:10.3727/000000001783992731 · Cited by 164
“genomic imprinting (75,86), and the repression of tu- mammalian cells is also assembled into a nucleaseresistant structure containing unusual nucleosomal mor suppressor genes in various cancers (43,89).”
BackgroundVarrault, A., Ciani, E., Apiou, F., Bilanges, B., Hoffmann, A., Pantaloni, C., Bockaert, J., Spengler, D., & Journot, L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8835 · Cited by 162
Regulation of DNA methylation of Rasgrf1
Yoon, B. J., Herman, H., Sikora, A., Smith, L. T., Plass, C., & Soloway, P. D. (2002) · Nature Genetics · doi:10.1038/ng795 · Cited by 160
Epigenomics: Genome-Wide Study of Methylation Phenomena
(2002) · Current Issues in Molecular Biology · doi:10.21775/cimb.004.111 · Cited by 150
Role of Epigenetics in Inflammation-Associated diseases
Shanmugam, M. K., & Sethi, G. (2013) · Subcellular Biochemistry · doi:10.1007/978-94-007-4525-4_27 · Cited by 141
Berner (1996) · doi:10.1002/(sici)1098-2264(199612)17:4
Metadata
- Authors
- Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., & Linehan, W. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-10-11
- Volume
- 91
- Issue
- 21
- Pages
- 9700-9704
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2150162153
- Cited by
- 1,529
- References
- 29
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.